


## TECHNICAL INFORMATION

Catalog Number: 199020  
**Ciprofloxacin Hydrochloride**

### Structure:



**Molecular Formula:** C<sub>17</sub>H<sub>18</sub>FN<sub>3</sub>O<sub>3</sub>·HCl

**Molecular Weight:** 367.84 (anhydrous)

**CAS #:** 86393-32-0

**Solubility:** Stock solutions can be prepared in water or 0.1 M NaOH (1 - 10 mg/ml). Solutions should be aliquoted and stored at -20°C for up to 6 months.

**Description:** An fluorinated quinolone antibacterial agent which is highly effective against a broad spectrum of bacteria and mycoplasma.

**Effective Working Concentration:** 5-25 ug/ml (average is 10 ug/ml). Ciprofloxacin hydrochloride is typically used for approximately 12 to 20 days in cell culture media with the media being changed every 3 to 4 days.

### References:

- Ba, B.B., et al., "Fully automated high-performance liquid chromatography of ciprofloxacin with direct injection of plasma and Mueller-Hinton broth for pharmacokinetic/ pharmacodynamic studies." *Journal of Chromatography B: Biomedical Sciences and Applications*, **v. 714:2**, 317-324 (1998).
- Djurdjevic, et al., "Study of solution equilibria between iron(III) ion and ciprofloxacin in pure nitrate ionic medium and micellar medium." *Polyhedron*, **v. 19:9**, 1085-1096 (2000).
- Garg, P., Sharma, S. and Rao, G.N., "Ciprofloxacin-resistant Pseudomonas keratitis." *Ophthalmology*, **v. 106:7**, 1319-1323 (1999).
- Grossman, R., et al., "A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis: the Canadian Ciprofloxacin Health Economic Study Group." *Chest*, **v. 113:1**, 131-141 (1998).
- Johnson, P.R., Liu Yin, J.A. and Tooth, J.A., "A randomized trial of high-dose ciprofloxacin versus azlocillin and netilmicin in the empirical therapy of febrile neutropenic patients." *J. Antimicrob. Chemother.*, **v. 30:2**, 203-214 (1992).
- Kaatz, G.W., et al., "Ciprofloxacin and rifampin, alone and in combination, for therapy of experimental Staphylococcus aureus endocarditis." *Antimicrob. Agents Chemother.*, **v. 33:8**, 1184-1187 (1989).
- Krumpe, P.E., et al., "Intravenous and oral mono- or combination-therapy in the treatment of severe infections: ciprofloxacin versus standard antibiotic therapy. Ciprofloxacin Study Group." *J. Antimicrob. Chemother.*, **v. 43 Suppl A**, 117-128 (1999).
- Lipsky, B.A., et al., "Sparfloxacin versus ciprofloxacin for the treatment of community-acquired, complicated skin and skin-structure infections." *Clin. Ther.*, **v. 21:4**, 675-690 (1999).
- Manceau, J., Gicquel, M., Laurentie, M. and Sanders, P., "Simultaneous determination of enrofloxacin and ciprofloxacin in

- animal biological fluids by high-performance liquid chromatography: Application in pharmacokinetic studies in pig and rabbit." *Journal of Chromatography B: Biomedical Sciences and Applications*, v. **726:1-2**, 175-184 (1999).
- Merck Index, **12th Ed.**, No. 2374.
  - Moreau, J.M., et al., "Effectiveness of ciprofloxacin-polystyrene sulfonate (PSS), ciprofloxacin and ofloxacin in a *Staphylococcus keratitis* model." *Curr. Eye Res.*, v. **17:8**, 808-812 (1998).
  - Thoppil, S.O. and Amin, P.D., "Stability indicating reversed-phase liquid chromatographic determination of ciprofloxacin as bulk drug and in pharmaceutical formulations." *Journal of Pharmaceutical and Biomedical Analysis*, v. **22:4**, 699-703 (2000).
  - Vega, E., Dabbene, M., Nassetta, M. and Sola, N., "Validation of a reversed-phase LC method for quantitative analysis of intravenous admixtures of ciprofloxacin and metronidazole." *Journal of Pharmaceutical and Biomedical Analysis*, v. **21:5**, 1003-1009 (1999).
  - Villavicencio, J., Asensio de Fernandez, M.E. and Ramirez, C.A., "Intravenous ciprofloxacin or ceftazidime in selected infections. A prospective, randomized, controlled study." *Am. J. Med.*, v. **87:5A**, 191S-194S (1989).